Herbs (Global Traditional) · Traditional Chinese Medicine
Corydalis (Corydalis yanhusuo) (Corydalis yanhusuo)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Corydalis yanhusuo is a traditional Chinese medicinal plant containing isoquinoline alkaloids, primarily tetrahydropalmatine and dehydrocorybulbine. These compounds demonstrate analgesic effects by modulating dopamine receptors and calcium channels in preclinical studies.
Corydalis yanhusuo is a perennial herb in the Papaveraceae family, native to China, with its rhizome (tuber) used medicinally as Yuan Hu in traditional Chinese medicine. The rhizomes are harvested and processed, often with vinegar to form alkaloid salts that enhance solubility, or used directly as crude powders, capsules, or liquid extracts.
Despite extensive traditional use, the research dossier reveals no human clinical trials, RCTs, or meta-analyses with PubMed PMIDs for C. yanhusuo. All available evidence comes from preclinical animal models and in-vitro studies examining analgesic, anti-inflammatory, antitumor, and cardioprotective effects of various alkaloid compounds.
No clinically studied dosage ranges are available from human trials. The Chinese Pharmacopoeia standardizes quality by tetrahydropalmatine content, but commercial products vary widely in alkaloid concentrations. Consult a healthcare provider before starting any new supplement.
Corydalis yanhusuo (Yan Hu Suo) is a medicinal tuber used primarily for its bioactive alkaloid content rather than macronutrient value. **Key Bioactive Compounds:** The tuber contains over 20 isoquinoline alkaloids, with the most pharmacologically significant being: • **Tetrahydropalmatine (THP / dl-THP):** ~0.1–0.5% of dried tuber weight; the principal analgesic alkaloid acting on dopamine receptors (D1/D2); bioavailability is moderate orally but enhanced by vinegar processing (cu zhi) which converts tertiary alkaloids to more soluble quaternary forms. • **Dehydrocorydaline (DHC):** ~0.05–0.3% of dried weight; exhibits anti-inflammatory and antitumor activity. • **Corydaline:** ~0.02–0.15%; contributes to analgesic and sedative effects. • **Palmatine:** ~0.03–0.2%; a protoberberine alkaloid with antimicrobial and anti-inflammatory properties. • **Berberine:** trace to ~0.05%; shares hepatoprotective and metabolic-regulating properties with Coptis species. • **Protopine:** ~0.01–0.1%; smooth muscle relaxant with antiarrhythmic potential. • **Glaucine and Canadine:** present in smaller quantities; contribute to antitussive and spasmolytic effects. **Total Alkaloid Content:** Typically 0.5–1.5% of dried tuber weight, varying by cultivation region, harvest time (collected before flowering), and processing method. Vinegar-processed (醋延胡索) preparations show 30–70% higher alkaloid extraction yield compared to unprocessed tuber. **Other Constituents:** • Organic acids (fumaric acid, succinic acid); • Sterols (β-sitosterol); • Polysaccharides (minor, not well-characterized); • Trace minerals including potassium, calcium, and iron (not standardized as nutritional sources). **Macronutrients:** Not consumed as a food; typical medicinal dose is 3–10 g of dried tuber per decoction. Starch comprises the bulk of tuber dry weight (~60–70%), with minimal protein (~3–5%) and negligible fat. **Bioavailability Notes:** Oral bioavailability of THP is estimated at ~40–50% in animal models, subject to significant first-pass hepatic metabolism (CYP3A4-mediated). Vinegar processing (traditional cu zhi method) increases solubility of alkaloids by converting free bases to salt forms, improving gastrointestinal absorption. Co-decoction with other herbs in traditional formulas may further modulate absorption kinetics.
Corydalis alkaloids, particularly tetrahydropalmatine, exert analgesic effects by blocking voltage-gated calcium channels and modulating dopamine D1 and D2 receptors. Dehydrocorybulbine demonstrates anti-inflammatory activity through inhibition of nuclear factor-kappa B (NF-κB) signaling pathways. The cardiovascular protective effects occur via regulation of Bcl-2 family proteins and stabilization of cardiac ion channels.
Current evidence for corydalis is limited primarily to animal studies and in vitro research. Rodent studies show significant pain reduction with doses equivalent to 100-300mg in humans, but no large-scale human clinical trials have been completed. Traditional use spans centuries in Chinese medicine, though standardized clinical data remains insufficient. Most research focuses on isolated alkaloid compounds rather than whole plant extracts.
Corydalis may cause drowsiness, dizziness, and digestive upset in some individuals. The herb can potentially interact with sedatives, blood thinners, and medications metabolized by cytochrome P450 enzymes due to its alkaloid content. Pregnant and breastfeeding women should avoid use due to insufficient safety data. Individuals with liver disease should exercise caution as alkaloids require hepatic metabolism.
